tiprankstipranks
Entrada Therapeutics Inc (TRDA)
NASDAQ:TRDA
US Market
TRDA
Entrada Therapeutics Inc
RESEARCH TOOLSreports
Want to see TRDA full AI Analyst Report?

Entrada Therapeutics Inc (TRDA) Stock News & Sentiment

159 Followers
Entrada Therapeutics Highlights Transformational Year and Pipeline Progress
Premium
Company Announcements
Entrada Therapeutics Highlights Transformational Year and Pipeline Progress
2d ago
8K
TRDA
Buy Rating Reaffirmed on TRDA as ENTR‑601‑44 Shows Clinically Meaningful Functional Gains and Higher-Dose Data Loom as Key Catalyst
Premium
Ratings
Buy Rating Reaffirmed on TRDA as ENTR‑601‑44 Shows Clinically Meaningful Functional Gains and Higher-Dose Data Loom as Key Catalyst
14d ago
TRDA
Entrada posts strong ENTR-601-44 Duchenne Phase 1/2 data
Premium
Company Announcements
Entrada posts strong ENTR-601-44 Duchenne Phase 1/2 data
14d ago
8K
TRDA
Advancing Exon-Skipping and Undervalued DM1 Collaboration Underscore Buy Rating on Entrada Therapeutics
Premium
Ratings
Advancing Exon-Skipping and Undervalued DM1 Collaboration Underscore Buy Rating on Entrada Therapeutics
3M ago
TRDA
Advancing DMD and DM1 Pipeline Positions Entrada for Multiple Near‑Term Catalysts and Upside Potential
Premium
Ratings
Advancing DMD and DM1 Pipeline Positions Entrada for Multiple Near‑Term Catalysts and Upside Potential
3M ago
TRDA
Entrada Therapeutics: Advancing ENTR-601-44 Positions Platform for Best-in-Class Dystrophin Restoration and Attractive Risk/Reward
Premium
Ratings
Entrada Therapeutics: Advancing ENTR-601-44 Positions Platform for Best-in-Class Dystrophin Restoration and Attractive Risk/Reward
3M ago
TRDA
Entrada Therapeutics: Advancing DMD and DM1 Pipeline with Emerging Ophthalmology Assets Supports Buy Rating and $20 Target
Premium
Ratings
Entrada Therapeutics: Advancing DMD and DM1 Pipeline with Emerging Ophthalmology Assets Supports Buy Rating and $20 Target
4M ago
TRDA
More TRDA News >

TRDA News on the Web

Entrada Therapeutics DMD Trial Shows Early Functional Gains, Clean Safety Profile
MarketBeat
Bullish
Entrada Therapeutics price target lowered to $10 from $19 at Roth Capital
TipRanks News
Bearish
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Entrada Therapeutics Inc (TRDA) and Contineum Therapeutics, Inc. Class A (CTNM)
TipRanks News
Bullish
Entrada Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
TipRanks News
Bearish
Entrada Therapeutics reports topline data from Cohort 1 of ELEVATE-44-201 study
TipRanks News
Bullish
Buy Rating Reaffirmed on TRDA as ENTR‑601‑44 Shows Clinically Meaningful Functional Gains and Higher-Dose Data Loom as Key Catalyst
TipRanks News
Bullish
Analysts Offer Insights on Healthcare Companies: Entrada Therapeutics Inc (TRDA) and Beam Therapeutics (BEAM)
TipRanks News
Bullish
Entrada Therapeutics reports Q1 EPS (95c), consensus ($1.02)
TipRanks News
Bullish

News Score - Last 7 Days

Not enough data to generate a sentiment score
TRDA
Sector Average
Media Buzz
This Week1 articles
Weekly Average3.25 articles
News Sentiment
This Week59%
Sector Average76%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is TRDA’s Media Buzz Sentiment?
1 articles about TRDA were published this week. In an average week, 3.25 articles are published.
    What is TRDA’s weekly average amount of articles?
    In an average week, 3.25 articles about TRDA are published.
      What is TRDA’s News Sentiment?
      59% of articles about TRDA were positive this week, compared to its sector average of 76%.
        Healthcare Stocks that are Trending in the News
        GOSSGossamer Bio
        RLAYRelay Therapeutics
        IMVTImmunovant
        ROIVRoivant Sciences
        PROKProKidney
        Showing the stocks with the most bullish news sentiment over the past week